Peroxisome Proliferator Activated Receptor gamma (PPAR γ) Agonist Rosiglitazone Ameliorate Airway Inflammation by Inhibiting Toll-Like Receptor 2 (TLR2)/Nod-Like Receptor with Pyrin Domain Containing 3 (NLRP3) Inflammatory Corpuscle Activation in Asthmatic Mice.

CONCLUSIONS PPARγ rosiglitazone ameliorates airway inflammation by inhibiting NF-kappaB expression in asthmatic mice, and further inhibits the activation of TLR2/NLRP3 inflammatory corpuscles. PMID: 30544130 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30544130?dopt=Abstract

Source: Medical Science Monitor - December 15, 2018 Category: Research Tags: Med Sci Monit Source Type: research